Aligos Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

ALGS$2.57-34.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Revenue from customers	$2,830	$741	$5,660	$2,017
Revenue from licensing agreements	39	—	27,817	—
Operating expenses:
Research and development	18,892	23,937	66,294	52,415
General and administrative	5,867	5,165	17,892	15,773
Total operating expenses	24,759	29,102	84,186	68,188
Loss from operations	(21,890)	(28,361)	(50,709)	(66,171)
Interest and other income, net	169	1,085	1,201	3,172
Change in fair value of 2023 Common Warrants	187	(4,205)	6,558	58,971
Loss before income tax	(21,534)	(31,481)	(42,950)	(4,028)
Income tax provision	(326)	(56)	(3,454)	(284)
Net loss	(21,860)	(31,537)	(46,404)	(4,312)
Other comprehensive income (loss):
Unrealized income (loss) on available-for-sale securities	—	35	(31)	4
Other comprehensive income (loss)	—	35	(31)	4
Comprehensive loss	$(21,860)	$(31,502)	$(46,435)	$(4,308)
Net loss per share, basic	$(2.09)	$(3.04)	$(4.45)	$(0.44)
Net loss per share, diluted	$(2.09)	$(3.04)	$(4.45)	$(0.44)
Weighted average shares of common stock, basic	10,461,954	10,369,535	10,432,125	9,716,895
Weighted average shares of common stock, diluted	10,461,954	10,369,535	10,432,125	9,716,895

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.